Cargando…
How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research
Tumor hypoxia is related with tumor aggressiveness, chemo- and radiotherapy resistance, and thus a poor clinical outcome. Therefore, over the past decades, every effort has been made to develop strategies to battle the negative prognostic influence of tumor hypoxia. For appropriate patient selection...
Autores principales: | De Bruycker, Sven, Vangestel, Christel, Staelens, Steven, Van den Wyngaert, Tim, Stroobants, Sigrid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211155/ https://www.ncbi.nlm.nih.gov/pubmed/30420794 http://dx.doi.org/10.1155/2018/4608186 |
Ejemplares similares
-
Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [(18)F]HX4 PET imaging study in colorectal cancer xenografts
por: De Bruycker, Sven, et al.
Publicado: (2019) -
Early Changes in [(18)F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts
por: Dockx, Yanina, et al.
Publicado: (2021) -
Preclinical Evaluation of a Novel (18)F-Labeled
dTCO-Amide Derivative for Bioorthogonal Pretargeted Positron Emission
Tomography Imaging
por: Ruivo, Eduardo, et al.
Publicado: (2020) -
Characterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis
por: Elvas, Filipe, et al.
Publicado: (2015) -
Translation of Preclinical PET Imaging Findings: Challenges and Motion Correction to Overcome the Confounding Effect of Anesthetics
por: Miranda, Alan, et al.
Publicado: (2021)